Comparative efficacy of tofisopam and placebo

Abstract
Tofisopam is a new agent marketed in Europe as a minor tranquilizer. A 4 wk double-blind trial of this drug compared with placebo was conducted in 57 outpatients with anxiety and depression. According to physician ratings and patient self-ratings, tofisopam was an effective anxiolytic agent for subjects with anxiety and depression. Twenty-one percent of the patients receiving tofisopam and 10% of those receiving placebo reported side effects. The drug was especially effective in the treatment of somatic difficulties.

This publication has 0 references indexed in Scilit: